| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Chief Medical Officer
1 company
Sciascia Thomas serves as a Chief Scientific Officer at TRVI. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $1.5M at current prices.
Historically, Sciascia Thomas's trades have earned a below-average insider score of 22/100 across 6 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -95.5%.
The biggest single holding is TRVI (~$1.5M) as Chief Scientific Officer. The recent filings there lean toward selling, a net 104,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | TRVI Trevi Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 2,631 | $6.60 | $17,364.60 | -1.2% | -13.0% | +73.1% | |
| Aug 19, 2024 | TRVI Trevi Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 16,496 | $2.96 | $48,882.60 | -7.0% | -5.1% | +146.5% | |
| Aug 16, 2024 | TRVI Trevi Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 31,505 | $2.77 | $87,227.69 | -12.5% | +3.2% | +171.5% | |
| May 29, 2024 | TRVI Trevi Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 53,368 | $2.55 | $136,109.75 | -19.9% | +14.6% | +150.4% |